author-photo

Ling Wang

Takeda Pharmaceutical Company

8

Papers

125

Citations

Citation Trend

Filter By

Papers (5) Sort By

Journal Conference Others

Bayesian interval-based oncology dose-finding design with repeated quasi-continuous toxicity model.

2021 Contemporary Clinical Trials
Show All
- Source
- Cite
- Save
Citations (0)
A Phase (ph) 1b/2 Study of TAK-659, an Investigational Dual FLT-3 and SYK Inhibitor, in Patients (Pts) with Relapsed or Refractory Acute Myelogenous Leukemia (R/R AML)

2016 Blood
Show All
- Source
- Cite
- Save
Citations (11)
Higher c-MYC Expression Is Associated with Ixazomib-Lenalidomide-Dexamethasone (IRd) Progression-Free Survival (PFS) Benefit Versus Placebo-Rd: Biomarker Analysis of the Phase 3 Tourmaline-MM1 Study in Relapsed/Refractory Multiple Myeloma (RRMM)

2016 Blood
Show All
- Source
- Cite
- Save
Citations (4)
Abstract B26: Phase 1b trial of investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in combination with docetaxel, paclitaxel/carboplatin, or gemcitabine in patients (pts) with solid tumors

2015 Molecular Cancer Therapeutics
Show All
- Source
- Cite
- Save
Citations (0)
Orteronel plus prednisone in patients with chemotherapy-naive metastatic castration-resistant prostate cancer (ELM-PC 4): a double-blind, multicentre, phase 3, randomised, placebo-controlled trial

2015 Lancet Oncology
Show All
- Source
- Cite
- Save
Citations (85)